PYPD Polypid Ltd

$PYPD An update on D-Plex during Investor Day can only mean that they have completed their CMC inspection and that no major issues were found. This is a good investment—LT

$PYPD Crazy price. So close to approval, partner, money in the bank, great partnership deal. This should make minimum 100m first year US only. Worth 15 right now. So many biotechs floundering with XBI up. Strange.

$PYPD fyi i bought yesterday me and some friends got all we wanted between 5.30 and 5.32

$PYPD There will be ATH before FDA decision. I think $5.8 - $6.5 If approva,l heading to $10 by the end of year. Next year $20.

$PYPD Nothing new.. MAA submission in October.. mgt hinted ealier maybe not in this month.. H1 October likely. Waiting game (PDUFA)

$PYPD we have 1352 watchers; 30% increase within a few months. Visibility is critical towards the PDUFA.

$PYPD resistance here is something beyond my understanding 2 months ahead PDUFA. with those chances for approval, with that deal and partnership, and most importantly with dplex technology just doesn't make sense to believe that this is fully priced. Which leads me to believe that no one knows about this ticker...

$PYPD Remember, scalable delivery platform very valuable. D-PLEX100 just starting point! You repeat, repeat, repeat. Look at Camurus AB, went from 250M market cap to 3.75B today.. 15X !! Polypid 100M at the moment. SKYROCKETING AHEAD.

$PYPD Market Maker doing it’s thing- no one really selling most shares are in strong hands - MM make money up or down . We dont care - stay focused on FDA approval. The company already making signals of a platform not just a one product…. Company. Make the math and if you are here consider yourself a lucky one.

$PYPD manufacturing facility inspection end of Oct press release in early November according to company

$PYPD Company is doing everything right. Gonna be a banger. One of the biggest surgical breakthrus in years. Can’t believe this isn’t $20 min. Market cap is going to explode upon approval in 2 months.

📅 CATALYST REMINDER | $PYPD October 28, 2026 — Investor Day PolyPid will outline pipeline strategy, discuss D-PLEX under FDA review and introduce the PD01B candidate during its virtual Investor Day. More details in our hub. #PYPD #Biotech #InvestorDay

$PYPD Crazy cheap. Market cap will be enormous after launch. Groundbreaking advance will be used as the standard surgery postop regimen. Can’t be overstated how big this is.

$PYPD do a deep dive into the partner and do a deeper into the partners parent company wow its impressive big huge money with smart people

$PYPD There will be info if a visit occured ... Because the official FDA registers are delayed for pending drugs, institutional traders use alternative "smoke signals" to figure out if PolyPid's factory in Israel was audited and whether they received a 483: • Tracking the FOIA Request Logs: Instead of waiting for a 483 to be published, track the FOIA Submission Log. If you see an entry where an investment firm or specialized law firm suddenly requests "Inspection records for PolyPid facility, September 2026," it is a definitive sign that the FDA audit team just left the building.

$PYPD $PYPD between the two Ph3s, they probably already manufactured 2000 doses. The manufacturing process has matured.

$PYPD my AI friend estimates risk of CRL at 15-20%. So even if you are really cautious you have a 4 in 5 chance of doubling your money in the next two months

$PYPD This company has all the ingredients only thing holding this back damn frigging 4.50 warrants 7.5m of them Stapled/ unstapled supply has to be coming from there. Frustrating stock. No reward.

$PYPD new investor day on 10/28/26. Update on the pending drug application with the fast approaching PDUFA date. Also, will introduce PD01B, a new product candidate based on PolyPid’s Kynatrix™ delivery technology, being developed for the treatment of diabetic foot infections. The event will feature Key Opinion Leader (“KOL”) Warren S. Joseph, DPM, FIDSA, a leading podiatric physician and a specialist in the treatment of lower extremity infections, widely recognized as an authority on the diagnosis and treatment of diabetic foot infections, who will discuss the clinical burden of diabetic foot infections, the limitations of current treatment approaches, and the potential role of locally delivered, controlled-release antibiotic therapy in this setting.

$PYPD I know everyone is like wtf about being back under 5. But honestly long term holders are still looking good as far as I'm concerned.